AN2 Therapeutics reports positive preclinical and Phase 1 data for Chagas disease drug
AN2 Therapeutics said results from a 28-day nonhuman primate study and a Phase 1 first-in-human study of its oral drug AN2-502998 for chronic Chagas disease were positive. The company plans to start a Phase 2 proof-of-concept study late this year, with the drug not yet approved and no FDA-approved Chagas treatment for adults currently available.
Key points
- NHP study: 100% of treated animals achieved parasite elimination at target exposures attainable in humans, maintained through four months after treatment ended
- Phase 1 study (NCT07024589) in healthy adult volunteers: generally well tolerated with no dose-limiting toxicities
- Company plans to initiate a Phase 2 proof-of-concept study late this year, in collaboration with DNDi
- AN2-502998 would be eligible for an FDA Tropical Disease Priority Review Voucher if approved
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.